LIFTT invests in immuno-oncology company NeoPhore

2024-02-01T10:35:01+01:001 February 2024|

NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three

1000Farmacie Secures $25 Million in Series A Funding, with an Additional $10 Million in Second Tranche Extension

2023-07-27T10:14:19+02:0027 July 2023|

1000Farmacie, the leading Italian pharmacy marketplace, announced today the successful completion of its second tranche of Series A funding, raising a total of $25 million. The company secured an additional $10 million in the extension round, highlighting investor confidence and further accelerating the company's mission to revolutionize the pharmaceutical industry.

LIFTT and the European Innovation Council (EIC) fund invest in Voiseed, the italian start-up seeking to revolutionise the entertainment industry

2023-02-07T11:43:33+01:007 February 2023|

LIFTTand the Venture Capital fund set up by the European Commission (EC) bet on artificial intelligence used in the professional dubbing sector, a 10-billion-dollar market.   The evergreen Venture Capital Holding LIFTT—as lead Investor—and the European Innovation Council Fund (EIC Fund) are investing 1 million euros in Voiseed, the Italian

LIFTT invests EUR 1 million in Betaglue Technologies

2023-03-09T14:53:02+01:0025 July 2022|

“BetaGlue brings together some of the world’s excellence in the field of cancer fighting, and their insight to combine existing and already active technologies in the market in an innovative way is simply formidable.”This month, we announced our investment in BetaGlue Technologies, a highly innovative life science company that we

Go to Top